A Multicentre, Non-Interventional, 3-Year Prospective Study Investigating the Real-Life Efficacy of Natalizumab and Integrated Patient Management Approach In Patients With Relapsing-Remitting Multiple Sclerosis

Trial Profile

A Multicentre, Non-Interventional, 3-Year Prospective Study Investigating the Real-Life Efficacy of Natalizumab and Integrated Patient Management Approach In Patients With Relapsing-Remitting Multiple Sclerosis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2016

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TRUST
  • Sponsors Biogen
  • Most Recent Events

    • 21 Apr 2016 First analysis of baseline data (n=427) presented at the 68th Annual Meeting of the American Academy of Neurology
    • 11 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top